Close Menu

semiconductor

The firms have already completed proof-of-concept studies for their semiconductor biosensor chips and Roswell plans to have the initial chips by 2021.

After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.

The Fox Chase Cancer Center has begun offering targeted sequencing to inform cancer treatment using an adaptation of Life Technologies' Ion Torrent AmpliSeq Cancer Panel via its CLIA-certified laboratory.

By Ben Butkus
DNA Electronics will begin pre-clinical pilot trials later this year to prepare its rapid, handheld, semiconductor-based DNA testing platform for clinical diagnostic use, the company said this week.

By Molika Ashford
A group from Intel's integrated biosystems lab is developing a label-free electrical detection method to detect DNA polymerase reactions on a chelator-modified field-effect transistor.

Building on its experience in different technology areas, the company is currently developing the single-molecule platform, which it plans to start testing next year with external collaborators such as the J. Craig Venter Institute.

Short Reads: Mar 24, 2009

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

NanoBioDiscovery, a division of NanoInk, expects to launch its Dip Pen Nanolithography technology-based instrumentation during the third quarter. At that time it also plans to start offering services based on the technology.

NASA's Ames Research Center has granted CombiMatrix a four-year, $858,298 contract to design and test a microfluidic system that can be used in a satellite-based integrated genetic analysis platform for assessing genetic changes in bacteria in space.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.